Global Capecitabine research

Capecitabine Comprehensive Study by Type (500 mg, 150 mg), Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Others), Drug Formulation (Tablets, Capsule) Players and Region - Global Market Outlook to 2028

Capecitabine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment that reduces or prevents the progression of cancer cells. This drug is used for the treatment of cancers such as colorectal cancer, breast cancer, and gastric cancer. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows the growth of tumor tissue. Abdominal pain, vomiting, diarrhea, weakness, and rashes are common adverse effects. Blood clotting issues, allergic responses, heart problems such as cardiomyopathy, and low blood cell counts are all serious adverse effects.Capecitabine is a chemotherapeutic drug. It is used to treat various types of cancer, including colon cancer.This growth is primarily driven by Growing Geriatric Population .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitK Unit
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Distributors sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Dr Reddy Laboratories Ltd (India), Fresenius SE & Co. KGaA (Germany), Cipla Inc. (India), Genentech, Inc. (United States), F. Hoffmann-La Roche (Switzerland), Sandoz (Germany), Ranbaxy Laboratories Ltd. (India), Zentiva N.V. (Czechia), Teva Pharma B.V. (Netherlands) and Accord Healthcare Ltd. (India), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In 2019, the Emcure Pharmaceutical (India) Company has launched generic breast cancer medicine, which is used to treat HER 2 negative patients. Hence, it will benefit the increased product portfolio of the company in the future.The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of a competitive advantage through combined collaborations.

Regulatory Insights:
According to the National Cancer Institute around 135,430 people are estimated to suffer from colon and rectum cancer and 50,260 people died of colon and rectum cancer in 2017.

Market Growth Drivers:
Growing Geriatric Population and Rise in Healthcare Expenditure and an Increase in Investment in Cancer Treatment or Assisted Programs by Governments

Challenges:
Lack of Awareness among the Consumers

Restraints:
Availability of Generic Drugs and Patent Expiration of Branded Drugs, Stringent Government Regulations Related to the Safety and High Cost of Capecitabine

Opportunities:
Huge Investment in R&D in Development of Drugs by Major Market Players and Growing Health Care Industry

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Capecitabine Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Capecitabine Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Capecitabine players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Capecitabine Study Sheds Light on
— The Capecitabine Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Capecitabine industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Capecitabine industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • 500 mg
  • 150 mg
By Application
  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
By Drug Formulation
  • Tablets
  • Capsule

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population
      • 3.2.2. Rise in Healthcare Expenditure and an Increase in Investment in Cancer Treatment or Assisted Programs by Governments
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Consumers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Capecitabine, by Type, Application, Drug Formulation and Region (value and volume ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Capecitabine (Value)
      • 5.2.1. Global Capecitabine by: Type (Value)
        • 5.2.1.1. 500 mg
        • 5.2.1.2. 150 mg
      • 5.2.2. Global Capecitabine by: Application (Value)
        • 5.2.2.1. Colon Cancer
        • 5.2.2.2. Rectal Cancer
        • 5.2.2.3. Breast Cancer
        • 5.2.2.4. Gastric Cancer
        • 5.2.2.5. Others
      • 5.2.3. Global Capecitabine by: Drug Formulation (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. Capsule
      • 5.2.4. Global Capecitabine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Capecitabine (Volume)
      • 5.3.1. Global Capecitabine by: Type (Volume)
        • 5.3.1.1. 500 mg
        • 5.3.1.2. 150 mg
      • 5.3.2. Global Capecitabine by: Application (Volume)
        • 5.3.2.1. Colon Cancer
        • 5.3.2.2. Rectal Cancer
        • 5.3.2.3. Breast Cancer
        • 5.3.2.4. Gastric Cancer
        • 5.3.2.5. Others
      • 5.3.3. Global Capecitabine by: Drug Formulation (Volume)
        • 5.3.3.1. Tablets
        • 5.3.3.2. Capsule
      • 5.3.4. Global Capecitabine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
  • 6. Capecitabine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dr Reddy Laboratories Ltd (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Fresenius SE & Co. KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cipla Inc. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Genentech, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ranbaxy Laboratories Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Zentiva N.V. (Czechia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharma B.V. (Netherlands)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Accord Healthcare Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Capecitabine Sale, by Type, Application, Drug Formulation and Region (value and volume ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Capecitabine (Value)
      • 7.2.1. Global Capecitabine by: Type (Value)
        • 7.2.1.1. 500 mg
        • 7.2.1.2. 150 mg
      • 7.2.2. Global Capecitabine by: Application (Value)
        • 7.2.2.1. Colon Cancer
        • 7.2.2.2. Rectal Cancer
        • 7.2.2.3. Breast Cancer
        • 7.2.2.4. Gastric Cancer
        • 7.2.2.5. Others
      • 7.2.3. Global Capecitabine by: Drug Formulation (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. Capsule
      • 7.2.4. Global Capecitabine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Capecitabine (Volume)
      • 7.3.1. Global Capecitabine by: Type (Volume)
        • 7.3.1.1. 500 mg
        • 7.3.1.2. 150 mg
      • 7.3.2. Global Capecitabine by: Application (Volume)
        • 7.3.2.1. Colon Cancer
        • 7.3.2.2. Rectal Cancer
        • 7.3.2.3. Breast Cancer
        • 7.3.2.4. Gastric Cancer
        • 7.3.2.5. Others
      • 7.3.3. Global Capecitabine by: Drug Formulation (Volume)
        • 7.3.3.1. Tablets
        • 7.3.3.2. Capsule
      • 7.3.4. Global Capecitabine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Capecitabine: by Type(USD Million)
  • Table 2. Capecitabine 500 mg , by Region USD Million (2017-2022)
  • Table 3. Capecitabine 150 mg , by Region USD Million (2017-2022)
  • Table 4. Capecitabine: by Application(USD Million)
  • Table 5. Capecitabine Colon Cancer , by Region USD Million (2017-2022)
  • Table 6. Capecitabine Rectal Cancer , by Region USD Million (2017-2022)
  • Table 7. Capecitabine Breast Cancer , by Region USD Million (2017-2022)
  • Table 8. Capecitabine Gastric Cancer , by Region USD Million (2017-2022)
  • Table 9. Capecitabine Others , by Region USD Million (2017-2022)
  • Table 10. Capecitabine: by Drug Formulation(USD Million)
  • Table 11. Capecitabine Tablets , by Region USD Million (2017-2022)
  • Table 12. Capecitabine Capsule , by Region USD Million (2017-2022)
  • Table 13. South America Capecitabine, by Country USD Million (2017-2022)
  • Table 14. South America Capecitabine, by Type USD Million (2017-2022)
  • Table 15. South America Capecitabine, by Application USD Million (2017-2022)
  • Table 16. South America Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 17. Brazil Capecitabine, by Type USD Million (2017-2022)
  • Table 18. Brazil Capecitabine, by Application USD Million (2017-2022)
  • Table 19. Brazil Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 20. Argentina Capecitabine, by Type USD Million (2017-2022)
  • Table 21. Argentina Capecitabine, by Application USD Million (2017-2022)
  • Table 22. Argentina Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 23. Rest of South America Capecitabine, by Type USD Million (2017-2022)
  • Table 24. Rest of South America Capecitabine, by Application USD Million (2017-2022)
  • Table 25. Rest of South America Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 26. Asia Pacific Capecitabine, by Country USD Million (2017-2022)
  • Table 27. Asia Pacific Capecitabine, by Type USD Million (2017-2022)
  • Table 28. Asia Pacific Capecitabine, by Application USD Million (2017-2022)
  • Table 29. Asia Pacific Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 30. China Capecitabine, by Type USD Million (2017-2022)
  • Table 31. China Capecitabine, by Application USD Million (2017-2022)
  • Table 32. China Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 33. Japan Capecitabine, by Type USD Million (2017-2022)
  • Table 34. Japan Capecitabine, by Application USD Million (2017-2022)
  • Table 35. Japan Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 36. India Capecitabine, by Type USD Million (2017-2022)
  • Table 37. India Capecitabine, by Application USD Million (2017-2022)
  • Table 38. India Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 39. South Korea Capecitabine, by Type USD Million (2017-2022)
  • Table 40. South Korea Capecitabine, by Application USD Million (2017-2022)
  • Table 41. South Korea Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 42. Taiwan Capecitabine, by Type USD Million (2017-2022)
  • Table 43. Taiwan Capecitabine, by Application USD Million (2017-2022)
  • Table 44. Taiwan Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 45. Australia Capecitabine, by Type USD Million (2017-2022)
  • Table 46. Australia Capecitabine, by Application USD Million (2017-2022)
  • Table 47. Australia Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Capecitabine, by Type USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Capecitabine, by Application USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 51. Europe Capecitabine, by Country USD Million (2017-2022)
  • Table 52. Europe Capecitabine, by Type USD Million (2017-2022)
  • Table 53. Europe Capecitabine, by Application USD Million (2017-2022)
  • Table 54. Europe Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 55. Germany Capecitabine, by Type USD Million (2017-2022)
  • Table 56. Germany Capecitabine, by Application USD Million (2017-2022)
  • Table 57. Germany Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 58. France Capecitabine, by Type USD Million (2017-2022)
  • Table 59. France Capecitabine, by Application USD Million (2017-2022)
  • Table 60. France Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 61. Italy Capecitabine, by Type USD Million (2017-2022)
  • Table 62. Italy Capecitabine, by Application USD Million (2017-2022)
  • Table 63. Italy Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 64. United Kingdom Capecitabine, by Type USD Million (2017-2022)
  • Table 65. United Kingdom Capecitabine, by Application USD Million (2017-2022)
  • Table 66. United Kingdom Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 67. Netherlands Capecitabine, by Type USD Million (2017-2022)
  • Table 68. Netherlands Capecitabine, by Application USD Million (2017-2022)
  • Table 69. Netherlands Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 70. Rest of Europe Capecitabine, by Type USD Million (2017-2022)
  • Table 71. Rest of Europe Capecitabine, by Application USD Million (2017-2022)
  • Table 72. Rest of Europe Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 73. MEA Capecitabine, by Country USD Million (2017-2022)
  • Table 74. MEA Capecitabine, by Type USD Million (2017-2022)
  • Table 75. MEA Capecitabine, by Application USD Million (2017-2022)
  • Table 76. MEA Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 77. Middle East Capecitabine, by Type USD Million (2017-2022)
  • Table 78. Middle East Capecitabine, by Application USD Million (2017-2022)
  • Table 79. Middle East Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 80. Africa Capecitabine, by Type USD Million (2017-2022)
  • Table 81. Africa Capecitabine, by Application USD Million (2017-2022)
  • Table 82. Africa Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 83. North America Capecitabine, by Country USD Million (2017-2022)
  • Table 84. North America Capecitabine, by Type USD Million (2017-2022)
  • Table 85. North America Capecitabine, by Application USD Million (2017-2022)
  • Table 86. North America Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 87. United States Capecitabine, by Type USD Million (2017-2022)
  • Table 88. United States Capecitabine, by Application USD Million (2017-2022)
  • Table 89. United States Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 90. Canada Capecitabine, by Type USD Million (2017-2022)
  • Table 91. Canada Capecitabine, by Application USD Million (2017-2022)
  • Table 92. Canada Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 93. Mexico Capecitabine, by Type USD Million (2017-2022)
  • Table 94. Mexico Capecitabine, by Application USD Million (2017-2022)
  • Table 95. Mexico Capecitabine, by Drug Formulation USD Million (2017-2022)
  • Table 96. Capecitabine Sales: by Type(K Unit)
  • Table 97. Capecitabine Sales 500 mg , by Region K Unit (2017-2022)
  • Table 98. Capecitabine Sales 150 mg , by Region K Unit (2017-2022)
  • Table 99. Capecitabine Sales: by Application(K Unit)
  • Table 100. Capecitabine Sales Colon Cancer , by Region K Unit (2017-2022)
  • Table 101. Capecitabine Sales Rectal Cancer , by Region K Unit (2017-2022)
  • Table 102. Capecitabine Sales Breast Cancer , by Region K Unit (2017-2022)
  • Table 103. Capecitabine Sales Gastric Cancer , by Region K Unit (2017-2022)
  • Table 104. Capecitabine Sales Others , by Region K Unit (2017-2022)
  • Table 105. Capecitabine Sales: by Drug Formulation(K Unit)
  • Table 106. Capecitabine Sales Tablets , by Region K Unit (2017-2022)
  • Table 107. Capecitabine Sales Capsule , by Region K Unit (2017-2022)
  • Table 108. South America Capecitabine Sales, by Country K Unit (2017-2022)
  • Table 109. South America Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 110. South America Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 111. South America Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 112. Brazil Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 113. Brazil Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 114. Brazil Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 115. Argentina Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 116. Argentina Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 117. Argentina Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 118. Rest of South America Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 119. Rest of South America Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 120. Rest of South America Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 121. Asia Pacific Capecitabine Sales, by Country K Unit (2017-2022)
  • Table 122. Asia Pacific Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 123. Asia Pacific Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 124. Asia Pacific Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 125. China Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 126. China Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 127. China Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 128. Japan Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 129. Japan Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 130. Japan Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 131. India Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 132. India Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 133. India Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 134. South Korea Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 135. South Korea Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 136. South Korea Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 137. Taiwan Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 138. Taiwan Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 139. Taiwan Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 140. Australia Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 141. Australia Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 142. Australia Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 143. Rest of Asia-Pacific Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 144. Rest of Asia-Pacific Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 145. Rest of Asia-Pacific Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 146. Europe Capecitabine Sales, by Country K Unit (2017-2022)
  • Table 147. Europe Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 148. Europe Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 149. Europe Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 150. Germany Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 151. Germany Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 152. Germany Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 153. France Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 154. France Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 155. France Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 156. Italy Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 157. Italy Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 158. Italy Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 159. United Kingdom Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 160. United Kingdom Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 161. United Kingdom Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 162. Netherlands Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 163. Netherlands Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 164. Netherlands Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 165. Rest of Europe Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 166. Rest of Europe Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 167. Rest of Europe Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 168. MEA Capecitabine Sales, by Country K Unit (2017-2022)
  • Table 169. MEA Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 170. MEA Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 171. MEA Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 172. Middle East Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 173. Middle East Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 174. Middle East Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 175. Africa Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 176. Africa Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 177. Africa Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 178. North America Capecitabine Sales, by Country K Unit (2017-2022)
  • Table 179. North America Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 180. North America Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 181. North America Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 182. United States Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 183. United States Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 184. United States Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 185. Canada Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 186. Canada Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 187. Canada Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 188. Mexico Capecitabine Sales, by Type K Unit (2017-2022)
  • Table 189. Mexico Capecitabine Sales, by Application K Unit (2017-2022)
  • Table 190. Mexico Capecitabine Sales, by Drug Formulation K Unit (2017-2022)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Capecitabine: by Type(USD Million)
  • Table 202. Capecitabine 500 mg , by Region USD Million (2023-2028)
  • Table 203. Capecitabine 150 mg , by Region USD Million (2023-2028)
  • Table 204. Capecitabine: by Application(USD Million)
  • Table 205. Capecitabine Colon Cancer , by Region USD Million (2023-2028)
  • Table 206. Capecitabine Rectal Cancer , by Region USD Million (2023-2028)
  • Table 207. Capecitabine Breast Cancer , by Region USD Million (2023-2028)
  • Table 208. Capecitabine Gastric Cancer , by Region USD Million (2023-2028)
  • Table 209. Capecitabine Others , by Region USD Million (2023-2028)
  • Table 210. Capecitabine: by Drug Formulation(USD Million)
  • Table 211. Capecitabine Tablets , by Region USD Million (2023-2028)
  • Table 212. Capecitabine Capsule , by Region USD Million (2023-2028)
  • Table 213. South America Capecitabine, by Country USD Million (2023-2028)
  • Table 214. South America Capecitabine, by Type USD Million (2023-2028)
  • Table 215. South America Capecitabine, by Application USD Million (2023-2028)
  • Table 216. South America Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 217. Brazil Capecitabine, by Type USD Million (2023-2028)
  • Table 218. Brazil Capecitabine, by Application USD Million (2023-2028)
  • Table 219. Brazil Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 220. Argentina Capecitabine, by Type USD Million (2023-2028)
  • Table 221. Argentina Capecitabine, by Application USD Million (2023-2028)
  • Table 222. Argentina Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 223. Rest of South America Capecitabine, by Type USD Million (2023-2028)
  • Table 224. Rest of South America Capecitabine, by Application USD Million (2023-2028)
  • Table 225. Rest of South America Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 226. Asia Pacific Capecitabine, by Country USD Million (2023-2028)
  • Table 227. Asia Pacific Capecitabine, by Type USD Million (2023-2028)
  • Table 228. Asia Pacific Capecitabine, by Application USD Million (2023-2028)
  • Table 229. Asia Pacific Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 230. China Capecitabine, by Type USD Million (2023-2028)
  • Table 231. China Capecitabine, by Application USD Million (2023-2028)
  • Table 232. China Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 233. Japan Capecitabine, by Type USD Million (2023-2028)
  • Table 234. Japan Capecitabine, by Application USD Million (2023-2028)
  • Table 235. Japan Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 236. India Capecitabine, by Type USD Million (2023-2028)
  • Table 237. India Capecitabine, by Application USD Million (2023-2028)
  • Table 238. India Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 239. South Korea Capecitabine, by Type USD Million (2023-2028)
  • Table 240. South Korea Capecitabine, by Application USD Million (2023-2028)
  • Table 241. South Korea Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 242. Taiwan Capecitabine, by Type USD Million (2023-2028)
  • Table 243. Taiwan Capecitabine, by Application USD Million (2023-2028)
  • Table 244. Taiwan Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 245. Australia Capecitabine, by Type USD Million (2023-2028)
  • Table 246. Australia Capecitabine, by Application USD Million (2023-2028)
  • Table 247. Australia Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 248. Rest of Asia-Pacific Capecitabine, by Type USD Million (2023-2028)
  • Table 249. Rest of Asia-Pacific Capecitabine, by Application USD Million (2023-2028)
  • Table 250. Rest of Asia-Pacific Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 251. Europe Capecitabine, by Country USD Million (2023-2028)
  • Table 252. Europe Capecitabine, by Type USD Million (2023-2028)
  • Table 253. Europe Capecitabine, by Application USD Million (2023-2028)
  • Table 254. Europe Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 255. Germany Capecitabine, by Type USD Million (2023-2028)
  • Table 256. Germany Capecitabine, by Application USD Million (2023-2028)
  • Table 257. Germany Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 258. France Capecitabine, by Type USD Million (2023-2028)
  • Table 259. France Capecitabine, by Application USD Million (2023-2028)
  • Table 260. France Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 261. Italy Capecitabine, by Type USD Million (2023-2028)
  • Table 262. Italy Capecitabine, by Application USD Million (2023-2028)
  • Table 263. Italy Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 264. United Kingdom Capecitabine, by Type USD Million (2023-2028)
  • Table 265. United Kingdom Capecitabine, by Application USD Million (2023-2028)
  • Table 266. United Kingdom Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 267. Netherlands Capecitabine, by Type USD Million (2023-2028)
  • Table 268. Netherlands Capecitabine, by Application USD Million (2023-2028)
  • Table 269. Netherlands Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 270. Rest of Europe Capecitabine, by Type USD Million (2023-2028)
  • Table 271. Rest of Europe Capecitabine, by Application USD Million (2023-2028)
  • Table 272. Rest of Europe Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 273. MEA Capecitabine, by Country USD Million (2023-2028)
  • Table 274. MEA Capecitabine, by Type USD Million (2023-2028)
  • Table 275. MEA Capecitabine, by Application USD Million (2023-2028)
  • Table 276. MEA Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 277. Middle East Capecitabine, by Type USD Million (2023-2028)
  • Table 278. Middle East Capecitabine, by Application USD Million (2023-2028)
  • Table 279. Middle East Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 280. Africa Capecitabine, by Type USD Million (2023-2028)
  • Table 281. Africa Capecitabine, by Application USD Million (2023-2028)
  • Table 282. Africa Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 283. North America Capecitabine, by Country USD Million (2023-2028)
  • Table 284. North America Capecitabine, by Type USD Million (2023-2028)
  • Table 285. North America Capecitabine, by Application USD Million (2023-2028)
  • Table 286. North America Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 287. United States Capecitabine, by Type USD Million (2023-2028)
  • Table 288. United States Capecitabine, by Application USD Million (2023-2028)
  • Table 289. United States Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 290. Canada Capecitabine, by Type USD Million (2023-2028)
  • Table 291. Canada Capecitabine, by Application USD Million (2023-2028)
  • Table 292. Canada Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 293. Mexico Capecitabine, by Type USD Million (2023-2028)
  • Table 294. Mexico Capecitabine, by Application USD Million (2023-2028)
  • Table 295. Mexico Capecitabine, by Drug Formulation USD Million (2023-2028)
  • Table 296. Capecitabine Sales: by Type(K Unit)
  • Table 297. Capecitabine Sales 500 mg , by Region K Unit (2023-2028)
  • Table 298. Capecitabine Sales 150 mg , by Region K Unit (2023-2028)
  • Table 299. Capecitabine Sales: by Application(K Unit)
  • Table 300. Capecitabine Sales Colon Cancer , by Region K Unit (2023-2028)
  • Table 301. Capecitabine Sales Rectal Cancer , by Region K Unit (2023-2028)
  • Table 302. Capecitabine Sales Breast Cancer , by Region K Unit (2023-2028)
  • Table 303. Capecitabine Sales Gastric Cancer , by Region K Unit (2023-2028)
  • Table 304. Capecitabine Sales Others , by Region K Unit (2023-2028)
  • Table 305. Capecitabine Sales: by Drug Formulation(K Unit)
  • Table 306. Capecitabine Sales Tablets , by Region K Unit (2023-2028)
  • Table 307. Capecitabine Sales Capsule , by Region K Unit (2023-2028)
  • Table 308. South America Capecitabine Sales, by Country K Unit (2023-2028)
  • Table 309. South America Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 310. South America Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 311. South America Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 312. Brazil Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 313. Brazil Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 314. Brazil Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 315. Argentina Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 316. Argentina Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 317. Argentina Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 318. Rest of South America Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 319. Rest of South America Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 320. Rest of South America Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 321. Asia Pacific Capecitabine Sales, by Country K Unit (2023-2028)
  • Table 322. Asia Pacific Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 323. Asia Pacific Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 324. Asia Pacific Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 325. China Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 326. China Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 327. China Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 328. Japan Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 329. Japan Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 330. Japan Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 331. India Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 332. India Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 333. India Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 334. South Korea Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 335. South Korea Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 336. South Korea Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 337. Taiwan Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 338. Taiwan Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 339. Taiwan Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 340. Australia Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 341. Australia Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 342. Australia Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 343. Rest of Asia-Pacific Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 344. Rest of Asia-Pacific Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 345. Rest of Asia-Pacific Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 346. Europe Capecitabine Sales, by Country K Unit (2023-2028)
  • Table 347. Europe Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 348. Europe Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 349. Europe Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 350. Germany Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 351. Germany Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 352. Germany Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 353. France Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 354. France Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 355. France Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 356. Italy Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 357. Italy Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 358. Italy Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 359. United Kingdom Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 360. United Kingdom Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 361. United Kingdom Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 362. Netherlands Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 363. Netherlands Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 364. Netherlands Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 365. Rest of Europe Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 366. Rest of Europe Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 367. Rest of Europe Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 368. MEA Capecitabine Sales, by Country K Unit (2023-2028)
  • Table 369. MEA Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 370. MEA Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 371. MEA Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 372. Middle East Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 373. Middle East Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 374. Middle East Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 375. Africa Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 376. Africa Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 377. Africa Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 378. North America Capecitabine Sales, by Country K Unit (2023-2028)
  • Table 379. North America Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 380. North America Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 381. North America Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 382. United States Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 383. United States Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 384. United States Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 385. Canada Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 386. Canada Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 387. Canada Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 388. Mexico Capecitabine Sales, by Type K Unit (2023-2028)
  • Table 389. Mexico Capecitabine Sales, by Application K Unit (2023-2028)
  • Table 390. Mexico Capecitabine Sales, by Drug Formulation K Unit (2023-2028)
  • Table 391. Research Programs/Design for This Report
  • Table 392. Key Data Information from Secondary Sources
  • Table 393. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Capecitabine: by Type USD Million (2017-2022)
  • Figure 5. Global Capecitabine: by Application USD Million (2017-2022)
  • Figure 6. Global Capecitabine: by Drug Formulation USD Million (2017-2022)
  • Figure 7. South America Capecitabine Share (%), by Country
  • Figure 8. Asia Pacific Capecitabine Share (%), by Country
  • Figure 9. Europe Capecitabine Share (%), by Country
  • Figure 10. MEA Capecitabine Share (%), by Country
  • Figure 11. North America Capecitabine Share (%), by Country
  • Figure 12. Global Capecitabine: by Type K Unit (2017-2022)
  • Figure 13. Global Capecitabine: by Application K Unit (2017-2022)
  • Figure 14. Global Capecitabine: by Drug Formulation K Unit (2017-2022)
  • Figure 15. South America Capecitabine Share (%), by Country
  • Figure 16. Asia Pacific Capecitabine Share (%), by Country
  • Figure 17. Europe Capecitabine Share (%), by Country
  • Figure 18. MEA Capecitabine Share (%), by Country
  • Figure 19. North America Capecitabine Share (%), by Country
  • Figure 20. Global Capecitabine share by Players 2022 (%)
  • Figure 21. Global Capecitabine share by Players (Top 3) 2022(%)
  • Figure 22. Global Capecitabine share by Players (Top 5) 2022(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Dr Reddy Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 25. Dr Reddy Laboratories Ltd (India) Revenue: by Geography 2022
  • Figure 26. Fresenius SE & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Fresenius SE & Co. KGaA (Germany) Revenue: by Geography 2022
  • Figure 28. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 29. Cipla Inc. (India) Revenue: by Geography 2022
  • Figure 30. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Genentech, Inc. (United States) Revenue: by Geography 2022
  • Figure 32. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2022
  • Figure 34. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Sandoz (Germany) Revenue: by Geography 2022
  • Figure 36. Ranbaxy Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 37. Ranbaxy Laboratories Ltd. (India) Revenue: by Geography 2022
  • Figure 38. Zentiva N.V. (Czechia) Revenue, Net Income and Gross profit
  • Figure 39. Zentiva N.V. (Czechia) Revenue: by Geography 2022
  • Figure 40. Teva Pharma B.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 41. Teva Pharma B.V. (Netherlands) Revenue: by Geography 2022
  • Figure 42. Accord Healthcare Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 43. Accord Healthcare Ltd. (India) Revenue: by Geography 2022
  • Figure 44. Global Capecitabine: by Type USD Million (2023-2028)
  • Figure 45. Global Capecitabine: by Application USD Million (2023-2028)
  • Figure 46. Global Capecitabine: by Drug Formulation USD Million (2023-2028)
  • Figure 47. South America Capecitabine Share (%), by Country
  • Figure 48. Asia Pacific Capecitabine Share (%), by Country
  • Figure 49. Europe Capecitabine Share (%), by Country
  • Figure 50. MEA Capecitabine Share (%), by Country
  • Figure 51. North America Capecitabine Share (%), by Country
  • Figure 52. Global Capecitabine: by Type K Unit (2023-2028)
  • Figure 53. Global Capecitabine: by Application K Unit (2023-2028)
  • Figure 54. Global Capecitabine: by Drug Formulation K Unit (2023-2028)
  • Figure 55. South America Capecitabine Share (%), by Country
  • Figure 56. Asia Pacific Capecitabine Share (%), by Country
  • Figure 57. Europe Capecitabine Share (%), by Country
  • Figure 58. MEA Capecitabine Share (%), by Country
  • Figure 59. North America Capecitabine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Dr Reddy Laboratories Ltd (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Cipla Inc. (India)
  • Genentech, Inc. (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • Sandoz (Germany)
  • Ranbaxy Laboratories Ltd. (India)
  • Zentiva N.V. (Czechia)
  • Teva Pharma B.V. (Netherlands)
  • Accord Healthcare Ltd. (India)
Additional players considered in the study are as follows:
Roche Holding AG (Switzerland) , Mylan (United States) , Hikma Pharmaceuticals (United Kingdom) , Reliance Group (India) , Hetero (India)
Select User Access Type

Key Highlights of Report


May 2023 249 Pages 55 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Capecitabine research Quantitative research analysis
Global Capecitabine research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Capecitabine Market are Dr Reddy Laboratories Ltd (India), Fresenius SE & Co. KGaA (Germany), Cipla Inc. (India), Genentech, Inc. (United States), F. Hoffmann-La Roche (Switzerland), Sandoz (Germany), Ranbaxy Laboratories Ltd. (India), Zentiva N.V. (Czechia), Teva Pharma B.V. (Netherlands) and Accord Healthcare Ltd. (India) etc.
Colon Cancer segment in Global market to hold robust market share owing to "Growing Geriatric Population ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Capecitabine market throughout the forecasted period.

Know More About Global Capecitabine research Report?

Have a Query? Click Here

Other Related Reports

Antiseptic Mouthwash Comprehensive Study by Type (Natural Mouthwash, Fluoride Mouthwash), Distribution Channel (Hypermarket & Supermarket, Convenience Stores, Online Sale) Players and Region - Global...
$ 3500
Adult Vaccines- Comprehensive Study by Type (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, Others), End Users (Medi...
$ 3750
Cardiac Stimulator Comprehensive Study by Type (Implantable Cardiac Stimulator, External Cardiac Stimulator), Application (Cardiopath, Heart First Aid, Other) Players and Region - Global Market Outlo...
$ 3500
Healthcare Distribution Comprehensive Study by Type (Pharmaceutical Product Distribution Services, Medical Device Distribution Services, Biopharmaceutical Product Distribution Services, Other Product...
$ 3650
Inhalable Drugs Comprehensive Study by Type (Dry Powder Formulation, Suspension Aerosol, Solution Aerosol), Application (Respiratory Disease, Non-respiratory Disease) Players and Region - Global Mark...
$ 3500
Chain Drugstores Comprehensive Study by Type (Regular Chain, Franchise Chain, Voluntary Chain), Application (B2B, B2C), Organization Size (Small & Medium Enterprises (SMEs), Large Enterprises), Distr...
$ 3350